Transgene Aktie

1,32 EUR ±0,00 EUR ±0,00 %

15:41:29

STU

1,34 EUR +0,01 EUR +0,45 %

29.12.2023

LSE

Transgene jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.172,77 Mio. EUR

Div. Rendite0,00%

WKN913048

ISINFR0005175080

SymbolTRGNF

Transgene Aktien News

Sortieren:Datum Meistgelesen

05.03.24GlobeNewswireTransgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

22.01.24GlobeNewswireTransgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22.01.24GlobeNewswireTransgene Announces Financial Calendar for 2024

08.01.24GlobeNewswireTransgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

04.01.24GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023

21.12.23BusinesswireTransgene Announces Upcoming Investor Meetings

05.12.23BusinesswireTransgene Strengthens its Leadership Team to Accelerate its Growth Strategy

07.11.23BusinesswireTransgene Reports Business Update and Q3 2023 Financial Position

10.10.23BusinesswireTransgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)

20.09.23BusinesswireTransgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

14.09.23BusinesswireTransgene Announces Upcoming Investor Meetings

17.07.23BusinesswireTransgene Receives $15.3 Million from the Sale of Securities Held for Sale

06.06.23BusinesswireTransgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

05.06.23BusinesswireTransgene Presents Immunological Data Demonstrating that TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

25.05.23BusinesswireTransgene and BioInvent Report Positive Phase Ia Data on Oncolytic Virus BT-001 in Solid Tumors

10.05.23BusinesswireTransgene provides business update and Q1 2023 financial position

10.05.23BusinesswireTransgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer

05.05.23BusinesswireTransgene’s Combined General Meeting of May 5, 2023

05.05.23BusinesswireTransgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

18.04.23BusinesswireNew Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

17.04.23BusinesswireTransgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

12.04.23BusinesswireTransgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

11.04.23BusinesswireTransgene: Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023

04.04.23BusinesswireTransgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers

27.03.23BusinesswireTransgene Announces Upcoming Investor Meetings

16.03.23BusinesswireTransgene: 2022 Full-year Results and Business Update

15.03.23BusinesswireTransgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

09.03.23BusinesswireTransgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

06.01.23BusinesswireTransgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

04.01.23BusinesswireTransgene Announces Financial Calendar for 2023

15.12.22BusinesswireTransgene Announces Upcoming Investor Meetings

14.11.22BusinesswireTransgene and BioInvent Joint Paper on BT-001 Wins JITC "Best Oncolytic and Local Immunotherapy Paper” Award for 2022

07.11.22BusinesswireTransgene Reports Business Update And Q3 2022 Financial Position

02.11.22BusinesswireTransgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers

Transgene News

Transgene News: auf dieser Seite finden Sie alle Transgene News und Nachrichten zur Transgene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Transgene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Transgene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.